ANTICANCER RESEARCH PANS OUT
ANTICANCER RESEARCH PANS OUT
复制标题
抗癌研究取得成功
DOI：
10.1021/cen-v077n044.p006
复制
发表时间：
1999
影响因子：
1.5
通讯作者：
S. Borman
中科院分区：
文献类型：
--
作者：
S. Borman
利用一系列小分子和一种聪明的筛选策略，哈佛大学的研究人员已经确定了一种名为monastrol的潜在抗癌药物，它通过抑制一种新的靶点--一种名为Eg 5的运动蛋白来阻断细胞分裂（有丝分裂）。这项研究不仅可以导致一类新的抗癌药物，而且可以更好地理解有丝分裂的机制。该化合物由博士后托马斯U. Mayer和Tarun M.卡普尔，研究生斯蒂芬J哈格蒂，和研究所研究员兰德尔W。在化学教授斯图尔特·L·金的小组中，Schreiber和哈佛医学院的细胞生物学教授Timothy J. Mitchison [ Science，286，971（1999）]。所有以前已知的阻断有丝分裂的小分子抗癌药物都与微管蛋白相互作用微管蛋白是微管的主要组成部分，微管是有丝分裂过程中分离分裂染色体的结构。微管蛋白是秋水仙碱、紫杉醇、阿霉素、依托泊苷、长春碱和维甲酸的靶点。
Using a collection of small molecules and a clever screening strategy, Harvard researchers have identified a potential anticancer agent called monastrol that blocks cell division (mitosis) by inhibiting a new target—a motor protein called Eg5. The study could lead not only to a novel class of anticancer drugs, but also to a better fundamental understanding of the mechanism of mitosis. The compound was identified by postdocs Thomas U. Mayer and Tarun M. Kapoor, graduate student Stephen J. Haggarty, and Institute Fellow Randall W. King in the groups of chemistry professor Stuart L. Schreiber of Harvard University and cell biology professor Timothy J. Mitchison of Harvard Medical School [ Science , 286 , 971 (1999)]. All previously known mitosis-blocking, small-molecule anticancer drugs interact with the protein tubulin—the main building block of microtubules, structures that separate dividing chromosomes during mitosis. Tubulin is the target for colchicine, Taxol, doxorubicin, etoposide, vinblastine, and vi...